TTM
$4.30
YoY change
-39.8%
5Y CAGR
+103.4%
Peak year (2024)
$5.78
Latest annual
$3.48
EPS (Diluted) history chart for Insulet (PODD) from 2002 to 2025
Latest: $3.48
EPS (Diluted) growth chart for Insulet (PODD) from 2002 to 2025
Latest: -39.8%
EPS (Diluted) history table for Insulet (PODD) from 2002 to 2025
| 2025 | $3.48 | -39.8% | −$2.30 | ||
| 2024 | $5.78 | +96.6% | +$2.84 | ||
| 2023 | $2.94 | +4368.1% | +$2.87 | ||
| 2022 | $0.07 | -73.7% | −$0.18 | ||
| 2021 | $0.25 | +150.0% | +$0.15 | ||
| 2020 | $0.10 | -47.4% | −$0.09 | ||
| 2019 | $0.19 | +251.9% | +$0.14 | ||
| 2018 | $0.05 | -111.7% | +$0.51 | ||
| 2017 | −$0.46 | -8.0% | +$0.04 | ||
| 2016 | −$0.50 | -61.2% | +$0.79 | ||
| 2015 | −$1.29 | +38.7% | −$0.36 | ||
| 2014 | −$0.93 | +12.0% | −$0.10 | ||
| 2013 | −$0.83 | -23.1% | +$0.25 | ||
| 2012 | −$1.08 | -11.5% | +$0.14 | ||
| 2011 | −$1.22 | -20.8% | +$0.32 | ||
| 2010 | −$1.54 | -42.5% | +$1.14 | ||
| 2009 | −$2.68 | -20.2% | +$0.68 | ||
| 2008 | −$3.36 | +4.7% | −$0.15 | ||
| 2007 | −$3.21 | -91.8% | +$35.98 | ||
| 2006 | −$39.19 | -44.8% | +$31.76 | ||
| 2005 | −$70.95 | +48.9% | −$23.31 | ||
| 2004 | −$47.64 | +8.6% | −$3.76 | ||
| 2003 | −$43.88 | +3.7% | −$1.58 | ||
| 2002 | −$42.30 | — | — |
- 2025$3.48-39.8%
- 2024$5.78+96.6%
- 2023$2.94+4368.1%
- 2022$0.07-73.7%
- 2021$0.25+150.0%
- 2020$0.10-47.4%
- 2019$0.19+251.9%
- 2018$0.05-111.7%
- 2017−$0.46-8.0%
- 2016−$0.50-61.2%
- 2015−$1.29+38.7%
- 2014−$0.93+12.0%
- 2013−$0.83-23.1%
- 2012−$1.08-11.5%
- 2011−$1.22-20.8%
- 2010−$1.54-42.5%
- 2009−$2.68-20.2%
- 2008−$3.36+4.7%
- 2007−$3.21-91.8%
- 2006−$39.19-44.8%
- 2005−$70.95+48.9%
- 2004−$47.64+8.6%
- 2003−$43.88+3.7%
- 2002−$42.30—
EPS (Diluted) values are taken from Insulet's reported income statements (quarterly 10-Q and annual 10-K filings with the U.S. Securities and Exchange Commission). Each row shows the period end date and the filing date. YoY compares each figure to the same period one year earlier. Amounts are in USD as filed.
About EPS (Diluted) at Insulet (PODD)
According to Insulet's latest reported financial statements, the company's current diluted EPS (TTM) is $4.30. Diluted earnings per share (EPS) is net income divided by the diluted weighted-average shares outstanding over the period. It expresses profit on a per-share basis — the figure investors use to value an individual share — and accounts for potential dilution from options, RSUs, and convertible securities.
Headline TTM above sums the four reported quarters through (reported ). Chart and table below cover the full reported history back to .
As of the 2025 fiscal year, Insulet (PODD) reported diluted EPS of $3.48 – plunged 39.8% year-over-year.
Across 2020–2025 (5 years), Insulet diluted EPS produced a CAGR of +103.4% – with mixed annual results across the window.
Between 2024 and 2025, Insulet diluted EPS plunged 39.8%, falling from $5.78 to $3.48.
The record annual diluted EPS stands at $5.78, reached in 2024; the historical low of −$70.95 was recorded in 2005.
Insulet EPS (Diluted) by Year
Insulet EPS (Diluted) 2025: $3.48
In 2025, Insulet reported diluted EPS of $3.48, plunged 39.8% below 2024.
Insulet EPS (Diluted) 2024: $5.78
Insulet diluted EPS in 2024 was $5.78, surged 96.6% from 2023. This figure represents the highest annual value in the available history.
Insulet EPS (Diluted) 2023: $2.94
2023's diluted EPS for Insulet came in at $2.94, surged 4368.1% from 2022.
Insulet EPS (Diluted) 2022: $0.07
Insulet posted diluted EPS of $0.07 in 2022, plunged 73.7% below 2021.
Insulet EPS (Diluted) 2021: $0.25
Insulet diluted EPS in 2021 was $0.25.
See more financial history for Insulet (PODD). Or calculate EPS yourself.
Sector peers by EPS (Diluted)
Healthcare peers of Insulet (PODD), ranked by their latest diluted EPS
| $22.95 | |
| $14.23 | |
| $13.23 | |
| $11.03 | |
| $7.28 | |
| $6.54 | |
| $3.59 | |
| $2.37 |
- $22.95
- $14.23
- $13.23
- $11.03
- $7.28
- $6.54
- $3.59
- $2.37
Frequently asked questions
Insulet (PODD) Key Financials
Charts, filings, and peer comparison for every metric
Explore more
Deep-dives across the income statement, cash flow, capital return, and valuation